Table 1.
Summary of significant (P < 0·05) changes in gene expression following 1α,25-dihydroxyvitamin D3 [1α,25(OH)2D3] treatment and Mycobacterium tuberculosis infection of human peripheral blood mononuclear cells (PBMC) and monocytes (MN)
| 1α,25(OH)2D3 versus 0·1% ethanol |
M. tuberculosis versus uninfected |
M. tuberculosis + 1α,25(OH)2D3 versus M. tuberculosis + 0·1% ethanol |
||||
|---|---|---|---|---|---|---|
| Gene | PBMC | MN | PBMC | MN | PBMC | MN |
| MMP-1 | – | – | ↑↑ | ↑↑ | – | – |
| MMP-7 | – | – | – | ↑↑ | – | ↓ |
| MMP-9 | ↓↓ | ↓↓ | – | – | ↓↓ | ↓ |
| MMP-10 | ↓↓ | ↓↓ | ↑↑ | ↑↑ | ↓ | ↓ |
| TIMP-1 | – | – | – | ↑ | ↑ | ↓ |
| TIMP-2 | ↑ | – | ↓ | ↓ | – | – |
| TIMP-3 | – | ↓ | – | – | – | ↓ |
| IL-10 | – | – | – | ↑↑ | ↑ | ↑ |
| 15-PGDH | ↑ | – | ↑ | ↑ | – | – |
| PGHS-2 | ↓ | – | ↑↑ | ↑↑ | – | ↑↑ |
↑, < 10-fold increase; ↑↑, ≥ 10-fold increase; ↓, < 10-fold decrease; ↓↓, ≥ 10-fold decrease; –, no significant effect.
IL-10, interleukin-10; MMP, matrix metalloproteinase; 15-PGDH, 15-hydroxyprostaglandin dehydrogenase; PGHS-2, prostaglandin H synthase-2; TIMP, tissue inhibitor of matrix metalloproteinase.